Effectiveness of Probiotics for Treatment of COVID-19: A Systematic Review and Meta-analysis
Hadeer Abdel-Aleem
Hassan Mohamed Tawfik (1), Mohamed Nazmy Farres (2), Rasha Samir (2,3), Mohamed
Nabil Badawy Al Ashram (2), Mina Michael Nesim (2), Mohamed Farouk Allam (1*)
(1) Department of Family Medicine, Faculty of
Medicine, Ain Shams University, Egypt
(2) Department of Internal Medicine, Faculty
of Medicine, Ain Shams University, Egypt
(3) Departemnt of Internal Medicine, Armed
Forces College of Medicine, Egypt
Universal Journal of Gastroenterology and
Hepatology 2023;1(1):17–25.
DOI:
10.31586/ujgh.2023.735
Abstract
Background: Recently
specific interactions and crosslinks between the gut microbiota and the lungs
have been recognized, particularly with regard to respiratory immune and
anti-microbial reactions. This is often known as the “gut-lung axis” or “a
common mucosal immunological system”. Objective: The aim of the current systematic review was to evaluate
evidence, from published clinical trials and cohort studies, if probiotics may
have an effect in improving and managing COVID-19 symptoms. Materials and methods: The available studies were searched through a
comprehensive search of electronic databases that included PubMed, Science
Direct, Scirus, ISI Web of Knowledge, Google Scholar and CENTRAL (Cochrane
Central Register of Controlled Trials), using a combination of the following
keywords: “COVID-19 OR SARS-CoV-2 AND Microbiota OR Probiotics” OR “Gut
Lung Axis”. The literature was reviewed until August 31, 2022. Results: Only 3 studies were included. One of them
evaluated the efficacy of probiotics in COVID-19 patients to obtain complete
remission of all signs and symptoms. The clinical trial proves that probiotics
have a significant effect on complete remission of all signs and symptoms of
COVID-19 patients with statistical significant difference. Only one clinical
trial out of the 3 included studies had evaluated the need for O2 therapy
during the study between the probiotics and control groups, but without
statistical significant difference. No statistical significant difference between the
probiotics group and placebo group was observed regarding fatal prognosis
during the only clinical trial that measured death as an outcome. Conclusion: We couldn’t judge on these results as they are insufficient
data for pooling and meta-analysis. However, what we can say is “Most probably
Probiotics have no role in treatment of COVID-19 infection”.
Keywords: COVID-19,
Probiotics, Management, Meta-analysis, Systematic Review.
Universal Journal of Gastroenterology and
Hepatology 2023;1(1):17–25.
https://www.scipublications.com/journal/index.php/UJGH/article/view/735
No hay comentarios:
Publicar un comentario
Nota: solo los miembros de este blog pueden publicar comentarios.